Confirmation of Specific Revision Items for the FY2026 Medical Fee Revision ① – Comparison of Inpatient Fees (Old vs. New), Evaluation and Schemes for Highly Acute Care Beds and Collaboration, Artificial Kidneys – HC Knowledge LLC

News Highlights

Specific revision items for the FY2026 medical fee revision have been confirmed, including a comparison of inpatient fees (old vs. new), evaluation and schemes related to highly acute care beds and collaboration, and artificial kidneys. This revision is closely related to the issues of medical M&A and business succession, such as mid-to-long-term management and succession strategies, economies of scale through group participation, and utilization of tax incentives including the transition to specific medical corporations and social medical corporations.

Perspective from the M&A Medical Editorial Department

The specific revision items for the FY2026 medical fee revision have been announced. In particular, the evaluation of highly acute care beds and the introduction of schemes to promote collaboration between medical institutions are directly linked to the management strategies of acute care hospitals. For example, functional differentiation through enhanced collaboration can provide an opportunity for small and medium-sized hospitals, which may find it difficult to maintain facility standards individually, to stabilize their management base through group affiliation. Furthermore, the review of evaluations related to artificial kidneys directly impacts the revenue structure of medical institutions with a large number of dialysis patients, making a comparative analysis with the current management situation essential. These revisions will affect the “appropriate” corporate valuation of target hospitals when considering future M&A and business succession, making early information gathering and strategic planning crucial.

Issues Highlighted by This News

• The review of evaluation for highly acute care beds affects the revenue structure and functional differentiation strategy of acute care hospitals.
• The introduction of collaboration schemes between medical institutions broadens the options for management stabilization through group affiliation.
• Revisions related to artificial kidneys have a direct impact on the profitability of medical institutions with dialysis functions.
• The urgent need to rebuild mid-to-long-term management and succession strategies with an eye on the revision cycle.

Practical Questions Arising from This News

• How specifically will the evaluation of highly acute care beds change, and how will it affect our hospital’s revenue?
• What are the advantages and disadvantages of group affiliation when utilizing collaboration schemes?
• How will the revenue and expenditure of the dialysis department change due to revisions in the calculation requirements and fees for artificial kidneys?

If You Feel “Should I Consult Too?”

In this medical fee revision, how might the changes, particularly regarding the evaluation of highly acute care beds, medical collaboration schemes, and artificial kidneys, impact your hospital’s revenue structure and future management strategy? If you are considering M&A or business succession to address issues such as responding to revision content, strengthening your management base by leveraging economies of scale, or dealing with challenges like lack of successors, consulting with experts at this time may be a step towards securing more favorable terms.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics as an M&A support institution certified by the Small and Medium Enterprise Agency, with a full success fee basis. We handle consultations with strict confidentiality. Free consultations here